APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intramuscular Injection of Pain Medication

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Intramuscular Injection of Pain Medication Market Outlook and Growth Opportunities 2026

23 December 2025205 pages

Choose your research edition.

Industry ResearchIntramuscular Injection of Pain Medication Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Intramuscular Injection of Pain Medication Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Intramuscular Injection of Pain Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intramuscular Injection of Pain Medication Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Intramuscular Injection of Pain Medication Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Intramuscular Injection of Pain Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Intramuscular Injection of Pain Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intramuscular Injection of Pain Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intramuscular Injection of Pain Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Intramuscular Injection of Pain Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Intramuscular Injection of Pain Medication market include Yangtze River Pharmaceutical Group (YRPG), Shijiazhuang Pharmaceutical Group, Sanofi, Humanwell Healthcare, Qilu Pharmaceutical, Novartis, Merck, Roche and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Intramuscular Injection of Pain Medication market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intramuscular Injection of Pain Medication and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intramuscular Injection of Pain Medication revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Intramuscular Injection of Pain Medication market.

Intramuscular Injection of Pain Medication Segment by Company

Yangtze River Pharmaceutical Group (YRPG)

Shijiazhuang Pharmaceutical Group

Sanofi

Humanwell Healthcare

Qilu Pharmaceutical

Novartis

Merck

Roche

Pfizer

China Resources Double Crane

Hengrui Medicine

Sinopharm Group

Fresenius Kabi

Northeast Pharmaceuticals

AstraZeneca

Hikma Pharmaceuticals

Grünenthal

Intramuscular Injection of Pain Medication Segment by Type

Opioid Analgesics (Opioids)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Local Anesthetics

Others

Intramuscular Injection of Pain Medication Segment by Application

Hospital

Clinic

Others

Intramuscular Injection of Pain Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Intramuscular Injection of Pain Medication status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Intramuscular Injection of Pain Medication key companies, revenue, market share, and recent developments.

3. To split the Intramuscular Injection of Pain Medication breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Intramuscular Injection of Pain Medication market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Intramuscular Injection of Pain Medication significant trends, drivers, influence factors in global and regions.

6. To analyze Intramuscular Injection of Pain Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intramuscular Injection of Pain Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intramuscular Injection of Pain Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intramuscular Injection of Pain Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intramuscular Injection of Pain Medication industry.

Chapter 3: Detailed analysis of Intramuscular Injection of Pain Medication company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Intramuscular Injection of Pain Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Intramuscular Injection of Pain Medication in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Intramuscular Injection of Pain Medication Industry Trends Table 2. Intramuscular Injection of Pain Medication Industry Drivers Table 3. Intramuscular Injection of Pain Medication Industry Opportunities and Challenges Table 4. Intramuscular Injection of Pain Medication Industry Restraints Table 5. Global Intramuscular Injection of Pain Medication Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Intramuscular Injection of Pain Medication Revenue Share by Company (2021-2026) Table 7. Global Intramuscular Injection of Pain Medication Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Intramuscular Injection of Pain Medication Key Company Manufacturing Base & Headquarters Table 9. Global Intramuscular Injection of Pain Medication Company, Product Type & Application Table 10. Global Intramuscular Injection of Pain Medication Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Intramuscular Injection of Pain Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Opioid Analgesics (Opioids) Table 15. Significant Companies of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Table 16. Significant Companies of Local Anesthetics Table 17. Significant Companies of Others Table 18. Global Intramuscular Injection of Pain Medication Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Intramuscular Injection of Pain Medication Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Intramuscular Injection of Pain Medication Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Intramuscular Injection of Pain Medication Sales Value Share by Type (2021-2026) Table 22. Global Intramuscular Injection of Pain Medication Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Significant Companies of Others Table 26. Global Intramuscular Injection of Pain Medication Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Intramuscular Injection of Pain Medication Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Intramuscular Injection of Pain Medication Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Intramuscular Injection of Pain Medication Sales Value Share by Application (2021-2026) Table 30. Global Intramuscular Injection of Pain Medication Sales Value Share by Application (2027-2032) Table 31. Global Intramuscular Injection of Pain Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Intramuscular Injection of Pain Medication Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Intramuscular Injection of Pain Medication Sales Value Share by Region (2021-2026) Table 34. Global Intramuscular Injection of Pain Medication Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Intramuscular Injection of Pain Medication Sales Value Share by Region (2027-2032) Table 36. Global Intramuscular Injection of Pain Medication Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Intramuscular Injection of Pain Medication Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Intramuscular Injection of Pain Medication Sales Value Market Share by Country (2021-2026) Table 39. Global Intramuscular Injection of Pain Medication Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Intramuscular Injection of Pain Medication Sales Value Market Share by Country (2027-2032) Table 41. Yangtze River Pharmaceutical Group (YRPG) Company Information Table 42. Yangtze River Pharmaceutical Group (YRPG) Business Overview Table 43. Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Product Portfolio Table 45. Yangtze River Pharmaceutical Group (YRPG) Recent Development Table 46. Shijiazhuang Pharmaceutical Group Company Information Table 47. Shijiazhuang Pharmaceutical Group Business Overview Table 48. Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Product Portfolio Table 50. Shijiazhuang Pharmaceutical Group Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sanofi Intramuscular Injection of Pain Medication Product Portfolio Table 55. Sanofi Recent Development Table 56. Humanwell Healthcare Company Information Table 57. Humanwell Healthcare Business Overview Table 58. Humanwell Healthcare Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Humanwell Healthcare Intramuscular Injection of Pain Medication Product Portfolio Table 60. Humanwell Healthcare Recent Development Table 61. Qilu Pharmaceutical Company Information Table 62. Qilu Pharmaceutical Business Overview Table 63. Qilu Pharmaceutical Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Qilu Pharmaceutical Intramuscular Injection of Pain Medication Product Portfolio Table 65. Qilu Pharmaceutical Recent Development Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis Intramuscular Injection of Pain Medication Product Portfolio Table 70. Novartis Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck Intramuscular Injection of Pain Medication Product Portfolio Table 75. Merck Recent Development Table 76. Roche Company Information Table 77. Roche Business Overview Table 78. Roche Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Roche Intramuscular Injection of Pain Medication Product Portfolio Table 80. Roche Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pfizer Intramuscular Injection of Pain Medication Product Portfolio Table 85. Pfizer Recent Development Table 86. China Resources Double Crane Company Information Table 87. China Resources Double Crane Business Overview Table 88. China Resources Double Crane Intramuscular Injection of Pain Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. China Resources Double Crane Intramuscular Injection of Pain Medication Product Portfolio Table 90. China Resources Double Crane Recent Development Table 91. Hengrui Medicine Company Information Table 92. Hengrui Medicine Business Overview Table 93. Hengrui Medicine Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Hengrui Medicine Intramuscular Injection of Pain Medication Product Portfolio Table 95. Hengrui Medicine Recent Development Table 96. Sinopharm Group Company Information Table 97. Sinopharm Group Business Overview Table 98. Sinopharm Group Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Sinopharm Group Intramuscular Injection of Pain Medication Product Portfolio Table 100. Sinopharm Group Recent Development Table 101. Fresenius Kabi Company Information Table 102. Fresenius Kabi Business Overview Table 103. Fresenius Kabi Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Fresenius Kabi Intramuscular Injection of Pain Medication Product Portfolio Table 105. Fresenius Kabi Recent Development Table 106. Northeast Pharmaceuticals Company Information Table 107. Northeast Pharmaceuticals Business Overview Table 108. Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio Table 110. Northeast Pharmaceuticals Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. AstraZeneca Intramuscular Injection of Pain Medication Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Hikma Pharmaceuticals Company Information Table 117. Hikma Pharmaceuticals Business Overview Table 118. Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio Table 120. Hikma Pharmaceuticals Recent Development Table 121. Grünenthal Company Information Table 122. Grünenthal Business Overview Table 123. Grünenthal Intramuscular Injection of Pain Medication Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Grünenthal Intramuscular Injection of Pain Medication Product Portfolio Table 125. Grünenthal Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Intramuscular Injection of Pain Medication Product Image Figure 2. Global Intramuscular Injection of Pain Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intramuscular Injection of Pain Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global Intramuscular Injection of Pain Medication Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Opioid Analgesics (Opioids) Image Figure 8. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Image Figure 9. Local Anesthetics Image Figure 10. Others Image Figure 11. Global Intramuscular Injection of Pain Medication Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Intramuscular Injection of Pain Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Intramuscular Injection of Pain Medication Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Others Image Figure 17. Global Intramuscular Injection of Pain Medication Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Intramuscular Injection of Pain Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Intramuscular Injection of Pain Medication Sales Value Share by Application (2021-2032) Figure 20. Global Intramuscular Injection of Pain Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Intramuscular Injection of Pain Medication Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Intramuscular Injection of Pain Medication Sales Value (2021-2032) & (US$ Million) Figure 23. North America Intramuscular Injection of Pain Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Intramuscular Injection of Pain Medication Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Intramuscular Injection of Pain Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Intramuscular Injection of Pain Medication Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Intramuscular Injection of Pain Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Intramuscular Injection of Pain Medication Sales Value (2021-2032) & (US$ Million) Figure 29. South America Intramuscular Injection of Pain Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Intramuscular Injection of Pain Medication Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Intramuscular Injection of Pain Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Opioid Analgesics (Opioids)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Local Anesthetics
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Yangtze River Pharmaceutical Group (YRPG)
  • Shijiazhuang Pharmaceutical Group
  • Sanofi
  • Humanwell Healthcare
  • Qilu Pharmaceutical
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • China Resources Double Crane
  • Hengrui Medicine
  • Sinopharm Group
  • Fresenius Kabi
  • Northeast Pharmaceuticals
  • AstraZeneca
  • Hikma Pharmaceuticals
  • Grünenthal

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Intramuscular Injection of Pain Medication Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Intramuscular Injection of Pain Medication Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Intramuscular Injection of Pain Medication Market Dynamics
  1. 2.1 Intramuscular Injection of Pain Medication Industry Trends
  2. 2.2 Intramuscular Injection of Pain Medication Industry Drivers
  3. 2.3 Intramuscular Injection of Pain Medication Industry Opportunities and Challenges
  4. 2.4 Intramuscular Injection of Pain Medication Industry Restraints
3 Intramuscular Injection of Pain Medication Market by Company
  1. 3.1 Global Intramuscular Injection of Pain Medication Company Revenue Ranking in 2025
  2. 3.2 Global Intramuscular Injection of Pain Medication Revenue by Company (2021-2026)
  3. 3.3 Global Intramuscular Injection of Pain Medication Company Ranking (2024-2026)
  4. 3.4 Global Intramuscular Injection of Pain Medication Company Manufacturing Base and Headquarters
  5. 3.5 Global Intramuscular Injection of Pain Medication Company Product Type and Application
  6. 3.6 Global Intramuscular Injection of Pain Medication Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Intramuscular Injection of Pain Medication Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Intramuscular Injection of Pain Medication Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Intramuscular Injection of Pain Medication Market by Type
  1. 4.1 Intramuscular Injection of Pain Medication Type Introduction
  2. 4.1.1 Opioid Analgesics (Opioids)
  3. 4.1.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  4. 4.1.3 Local Anesthetics
  5. 4.1.4 Others
  6. 4.2 Global Intramuscular Injection of Pain Medication Sales Value by Type
  7. 4.2.1 Global Intramuscular Injection of Pain Medication Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Intramuscular Injection of Pain Medication Sales Value by Type (2021-2032)
  9. 4.2.3 Global Intramuscular Injection of Pain Medication Sales Value Share by Type (2021-2032)
5 Intramuscular Injection of Pain Medication Market by Application
  1. 5.1 Intramuscular Injection of Pain Medication Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Intramuscular Injection of Pain Medication Sales Value by Application
  6. 5.2.1 Global Intramuscular Injection of Pain Medication Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Intramuscular Injection of Pain Medication Sales Value by Application (2021-2032)
  8. 5.2.3 Global Intramuscular Injection of Pain Medication Sales Value Share by Application (2021-2032)
6 Intramuscular Injection of Pain Medication Regional Value Analysis
  1. 6.1 Global Intramuscular Injection of Pain Medication Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intramuscular Injection of Pain Medication Sales Value by Region (2021-2032)
  3. 6.2.1 Global Intramuscular Injection of Pain Medication Sales Value by Region: 2021-2026
  4. 6.2.2 Global Intramuscular Injection of Pain Medication Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Intramuscular Injection of Pain Medication Sales Value (2021-2032)
  7. 6.3.2 North America Intramuscular Injection of Pain Medication Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Intramuscular Injection of Pain Medication Sales Value (2021-2032)
  10. 6.4.2 Europe Intramuscular Injection of Pain Medication Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Intramuscular Injection of Pain Medication Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Intramuscular Injection of Pain Medication Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Intramuscular Injection of Pain Medication Sales Value (2021-2032)
  16. 6.6.2 South America Intramuscular Injection of Pain Medication Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Intramuscular Injection of Pain Medication Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Intramuscular Injection of Pain Medication Sales Value Share by Country, 2025 VS 2032
7 Intramuscular Injection of Pain Medication Country-level Value Analysis
  1. 7.1 Global Intramuscular Injection of Pain Medication Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Intramuscular Injection of Pain Medication Sales Value by Country (2021-2032)
  3. 7.2.1 Global Intramuscular Injection of Pain Medication Sales Value by Country (2021-2026)
  4. 7.2.2 Global Intramuscular Injection of Pain Medication Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Intramuscular Injection of Pain Medication Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Intramuscular Injection of Pain Medication Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Intramuscular Injection of Pain Medication Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yangtze River Pharmaceutical Group (YRPG)
  2. 8.1.1 Yangtze River Pharmaceutical Group (YRPG) Company Information
  3. 8.1.2 Yangtze River Pharmaceutical Group (YRPG) Business Overview
  4. 8.1.3 Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Product Portfolio
  6. 8.1.5 Yangtze River Pharmaceutical Group (YRPG) Recent Developments
  7. 8.2 Shijiazhuang Pharmaceutical Group
  8. 8.2.1 Shijiazhuang Pharmaceutical Group Company Information
  9. 8.2.2 Shijiazhuang Pharmaceutical Group Business Overview
  10. 8.2.3 Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Product Portfolio
  12. 8.2.5 Shijiazhuang Pharmaceutical Group Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Intramuscular Injection of Pain Medication Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Humanwell Healthcare
  20. 8.4.1 Humanwell Healthcare Company Information
  21. 8.4.2 Humanwell Healthcare Business Overview
  22. 8.4.3 Humanwell Healthcare Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Humanwell Healthcare Intramuscular Injection of Pain Medication Product Portfolio
  24. 8.4.5 Humanwell Healthcare Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Intramuscular Injection of Pain Medication Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Intramuscular Injection of Pain Medication Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Intramuscular Injection of Pain Medication Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Intramuscular Injection of Pain Medication Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Intramuscular Injection of Pain Medication Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 China Resources Double Crane
  56. 8.10.1 China Resources Double Crane Company Information
  57. 8.10.2 China Resources Double Crane Business Overview
  58. 8.10.3 China Resources Double Crane Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  59. 8.10.4 China Resources Double Crane Intramuscular Injection of Pain Medication Product Portfolio
  60. 8.10.5 China Resources Double Crane Recent Developments
  61. 8.11 Hengrui Medicine
  62. 8.11.1 Hengrui Medicine Company Information
  63. 8.11.2 Hengrui Medicine Business Overview
  64. 8.11.3 Hengrui Medicine Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hengrui Medicine Intramuscular Injection of Pain Medication Product Portfolio
  66. 8.11.5 Hengrui Medicine Recent Developments
  67. 8.12 Sinopharm Group
  68. 8.12.1 Sinopharm Group Company Information
  69. 8.12.2 Sinopharm Group Business Overview
  70. 8.12.3 Sinopharm Group Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sinopharm Group Intramuscular Injection of Pain Medication Product Portfolio
  72. 8.12.5 Sinopharm Group Recent Developments
  73. 8.13 Fresenius Kabi
  74. 8.13.1 Fresenius Kabi Company Information
  75. 8.13.2 Fresenius Kabi Business Overview
  76. 8.13.3 Fresenius Kabi Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Fresenius Kabi Intramuscular Injection of Pain Medication Product Portfolio
  78. 8.13.5 Fresenius Kabi Recent Developments
  79. 8.14 Northeast Pharmaceuticals
  80. 8.14.1 Northeast Pharmaceuticals Company Information
  81. 8.14.2 Northeast Pharmaceuticals Business Overview
  82. 8.14.3 Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio
  84. 8.14.5 Northeast Pharmaceuticals Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Intramuscular Injection of Pain Medication Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Hikma Pharmaceuticals
  92. 8.16.1 Hikma Pharmaceuticals Company Information
  93. 8.16.2 Hikma Pharmaceuticals Business Overview
  94. 8.16.3 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio
  96. 8.16.5 Hikma Pharmaceuticals Recent Developments
  97. 8.17 Grünenthal
  98. 8.17.1 Grünenthal Company Information
  99. 8.17.2 Grünenthal Business Overview
  100. 8.17.3 Grünenthal Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Grünenthal Intramuscular Injection of Pain Medication Product Portfolio
  102. 8.17.5 Grünenthal Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst